1
|
Balgansuren G, Sprague M, Peterson P, Shenavar Y, Ng A, Regen L, Shelton N, Petersdorf E. HLA-B leader genotypes in a clinical population. HLA 2023. [PMID: 36929133 DOI: 10.1111/tan.15022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 02/15/2023] [Accepted: 02/15/2023] [Indexed: 03/18/2023]
Abstract
The -21 dimorphism in the leader sequences of HLA-B exon 1 is associated with risk of graft-versus-host disease (GVHD), relapse and overall survival after unrelated donor hematopoietic cell transplantation (HCT), haploidentical HCT and cord blood transplantation. Consideration of the leader dimorphism in the prospective selection of allogeneic donors for HCT may help to lower risks for patients, but requires understanding of the frequencies of the leader in patients and candidate transplant donors. We defined the frequencies of the HLA-B leader, and its association to HLA-B Bw4/Bw6 and C1/C2 KIR epitopes. Sequence variants of rs1050458 of exon 1 position -21 for 11,126 haplotypes were analyzed from high resolution HLA typing of over 5500 study subjects. HLA typing was performed by TruSight/AlloSeq NGS and analyzed using TruSight/AlloSeq Assign software. HLA-B Bw4/Bw6 and C1/C2 KIR epitopes were defined based on established sequence alignments and nomenclature. Alleles at rs1050458 of HLA-B exon 1 were validated as dimorphic: rs1050458-C or -T variants encoding threonine (T) or methionine (M) at anchor position 2 (P2) of nonameric HLA-B leader peptides, respectfully. No additional variants were observed. Among study subjects, 70% of HLA-B haplotypes encoded T-leader and 30% encoded M-leader sequences. The genotype frequencies of TT, MT, and MM were consistent among patient, related, and unrelated donor groups. The associations of M/T leader, Bw4/Bw6, and C1/C2 enhanced understanding of the Class I features involved in the innate immune response. A population of patients and transplant donors confirms the rs1050458 leader dimorphism and its association with HLA-B Bw4/Bw6 and C1/C2 KIR features.
Collapse
Affiliation(s)
- Gansuvd Balgansuren
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.,Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA
| | - Maggie Sprague
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Paula Peterson
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Yasaman Shenavar
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Ada Ng
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Lois Regen
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Nakita Shelton
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Effie Petersdorf
- Clinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.,Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA
| |
Collapse
|
2
|
Balgansuren G, Sprague M, Peterson P, Shenavar Y, Ng A, Shelton N, Regen L. P004 Novel and hybrid HLA-DPA1 alllele inherited from both parents. Hum Immunol 2019. [DOI: 10.1016/j.humimm.2019.07.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Balgansuren G, Regen L, Sprague M, Shelton N, Petersdorf E, Hansen JA. Identification of the rs9277534 HLA-DP expression marker by next generation sequencing for the selection of unrelated donors for hematopoietic cell transplantation. Hum Immunol 2019; 80:828-833. [PMID: 31176504 DOI: 10.1016/j.humimm.2019.05.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 05/10/2019] [Accepted: 05/23/2019] [Indexed: 11/18/2022]
Abstract
Mismatching of an unrelated donor against a high-expression HLA-DPB1 recipient allele is associated with a high risk of graft-versus-host disease and mortality. The Seattle Cancer Care Alliance (SCCA) and Fred Hutchinson Cancer Research Center transplant program employs an algorithm to match for HLA-A, B, C, DRB1, DQB1 and DPB1 alleles (12/12) and to avoid, whenever possible, donor mismatching against a recipient high-expression HLA-DPB1 allele. HLA-DPB1 expression is associated with the rs9277534 A/G polymorphism located in the 3'UTR of the HLA-DPB1 gene. Next generation sequencing of HLA-DPB1 using the Illumina TruSight HLA V2 Sequencing Panel and Conexio Assign software analyses provides information on rs9277534 variants without the need for any additional SNP testing. Here we present the molecular location of rs9277534 in NGS data and discuss the challenges to resolve HLA-DPB1 ambiguities.
Collapse
Affiliation(s)
- Gansuvd Balgansuren
- Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; University of Washington, Seattle, WA, USA.
| | - Lois Regen
- Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA
| | - Maggie Sprague
- Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA
| | - Nakita Shelton
- Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA
| | - Effie Petersdorf
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA
| | - John A Hansen
- Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA
| |
Collapse
|
4
|
Fatobene G, Storer BE, Salit RB, Lee SJ, Martin PJ, Cheng GS, Carpenter PA, Balgansuren G, Petersdorf EW, Delaney C, Sandmaier BM, Milano F, Flowers ME. Disability related to chronic graft - versus-host disease after alternative donor hematopoietic cell transplantation. Haematologica 2018; 104:835-843. [PMID: 30442722 PMCID: PMC6442956 DOI: 10.3324/haematol.2018.202754] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 11/08/2018] [Indexed: 12/21/2022] Open
Abstract
We determined the incidence of disability related to chronic graft-versus-host disease (bronchiolitis obliterans, grade ≥2 keratoconjunctivitis sicca, sclerotic features or esophageal stricture) for three categories of alternative donor: cord blood, haplorelated marrow or peripheral blood with post-transplant cyclophosphamide, and unrelated single HLA-allele mismatched peripheral blood. Among 396 consecutive hematopoietic cell transplant recipients, 129 developed chronic graft-versus-host disease with 3-year cumulative incidences of 8% for cord blood, 24% for haplorelated grafts, and 55% for unrelated single HLA-allele mismatched peripheral blood. Disability rates were significantly lower for cord blood [hazard ratio (HR) 0.13; 95% confidence interval (CI): 0.1-0.4] and for the haplorelated group (HR 0.31; 95% CI: 0.1-0.7) compared to the rate in the group transplanted with unrelated single HLA-allele mismatched peripheral blood. Cord blood recipients were also >2-fold more likely to return to work/school within 3 years from the onset of chronic graft-versus-host disease (HR 2.54; 95% CI: 1.1-5.7, P=0.02), and the haplorelated group trended similarly (HR 2.38; 95% CI: 1.0-5.9, P=0.06). Cord blood recipients were more likely to discontinue immunosuppression than were recipients of unrelated single HLA-allele mismatched peripheral blood (HR 3.96; 95% CI: 1.9-8.4, P=0.0003), similarly to the haplorelated group (HR 4.93; 95% CI: 2.2-11.1, P=0.0001). Progression-free survival and non-relapse mortality did not differ between groups grafted from different types of donors. Our observations that, compared to recipients of unrelated single HLA-allele mismatched peripheral blood, recipients of cord blood and haplorelated grafts less often developed disability related to chronic graft-versus-host disease, and were more likely to resume work/school, should help better counseling of pre-hematopoietic cell transplant candidates.
Collapse
Affiliation(s)
- Giancarlo Fatobene
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,Universidade de Sao Paulo, Hospital das Clinicas, SP, Brazil
| | - Barry E Storer
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA
| | - Rachel B Salit
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Stephanie J Lee
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Paul J Martin
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Guang-Shing Cheng
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Paul A Carpenter
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Gansuvd Balgansuren
- University of Washington, Division of Medical Oncology, Seattle, WA, USA.,Seattle Cancer Care Alliance, Seattle, WA, USA
| | - Effie W Petersdorf
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Colleen Delaney
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Brenda M Sandmaier
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Filippo Milano
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| | - Mary E Flowers
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA .,University of Washington, Division of Medical Oncology, Seattle, WA, USA
| |
Collapse
|
5
|
Oakley F, Peterson P, McElhone S, Williams RP, Witherspoon R, Regen LE, Fang M, Balgansuren G. OR6 Next generation sequencing HLA typing in patients with copy neutral loss of heterozygosity. Hum Immunol 2017. [DOI: 10.1016/j.humimm.2017.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Sprague M, Peterson P, Wohlwend G, Shenavar Y, Kellum C, Regen LE, Balgansuren G. P248 Next generation sequencing reveals a novel hla-a*24 allele associated with hla-dqb1*06:10 in asians. Hum Immunol 2017. [DOI: 10.1016/j.humimm.2017.06.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
McLendon DL, Menninger O, Lei M, Balgansuren G. P141 CDC-T-AHG positive, flow negative crossmatch due to HLA-B57 specific IgM antibody: Case study. Hum Immunol 2016. [DOI: 10.1016/j.humimm.2016.07.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Williams R, Warnock S, Regen L, Sprague M, Balgansuren G. Resolution of HLA-A*68:11N allele by One Lambda labtype® reverse sequence specific oligonucleotide typing kit. Hum Immunol 2015. [DOI: 10.1016/j.humimm.2015.07.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
McFarland C, Ng A, Regen L, Balgansuren G. Tri-allelic TPOX genotype observed in engraftment monitoring baseline. Hum Immunol 2015. [DOI: 10.1016/j.humimm.2015.07.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Tian R, Hodges E, Young C, DeOliveira A, Wegner WE, Balgansuren G, Chen DF. P078. Hum Immunol 2014. [DOI: 10.1016/j.humimm.2014.08.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Balgansuren G, Clark A, DeOliveira A, Deitz J, Chen DF. 1038-LBP. Hum Immunol 2014. [DOI: 10.1016/j.humimm.2014.01.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Tian R, DeOliveira A, Balgansuren G, Chen DF. 121-P. Hum Immunol 2012. [DOI: 10.1016/j.humimm.2012.07.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Balgansuren G, Clark A, Crews GT, Baker M, Wegner WE, Chen DF. 179-P. Hum Immunol 2012. [DOI: 10.1016/j.humimm.2012.07.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Crews GT, Wegner WE, Balgansuren G, Chen DF. 190-P. Hum Immunol 2012. [DOI: 10.1016/j.humimm.2012.07.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Nie X, Zhu C, Song Y, Zhang Y, Zhuang Y, Liu Y, DeOliveira A, Holeman B, Young C, Balgansuren G, Chen DF. 120-P A potential novel HLA-DRB1*03 allele identified by sequence-based typing in a potential chinese HSCT donor. Hum Immunol 2011. [DOI: 10.1016/j.humimm.2011.07.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Balgansuren G, DeOliveira A, Holeman B, Young C, Clark A, Chen DF. 3-OR A challenge in HLA typing in patients with refractory aplastic anemia and haplotype specific preferential amplification. Hum Immunol 2011. [DOI: 10.1016/j.humimm.2011.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
17
|
Balgansuren G, Peel L, Crews T, Clark A, Burgess B, Wegner W, Nie X, Adams PW, Chen DF. 5-P Optimized pronase treatment eliminates false positive B cell crossmatch caused by desensitization protocol with rituximab: High dose of pronase treatment affects CD19 expression. Hum Immunol 2011. [DOI: 10.1016/j.humimm.2011.07.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
DeOliveira A, Balgansuren G, Holeman B, Chen DF. 109-P: Ambiguity Rates in HLA Sequence-Based Typing. Hum Immunol 2010. [DOI: 10.1016/j.humimm.2010.06.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
19
|
Andrades P, Asiedu C, Rodriguez C, Goodwin J, Deckard LA, Jargal U, Balgansuren G, Thomas JM. Insulin secretion from pancreatic islets in fibrin glue clots at different fibrinogen and thrombin concentrations. Transplant Proc 2007; 39:1607-8. [PMID: 17580199 DOI: 10.1016/j.transproceed.2007.01.078] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2006] [Accepted: 01/16/2007] [Indexed: 10/23/2022]
Abstract
BACKGROUND Fibrin glue has proven to be a good delivery system for cell transplantation but the factors that influence the fibrin-cell relationships are not well understood. The purpose of this study was to assess the effect of different concentrations of fibrin glue components (thrombin and fibrinogen) on the function of pancreatic islets. METHOD Islets were isolated from rat pancreata and combined with 6 different fibrin glue formulations. Each islet sample was incubated sequentially with RPMI containing low and high glucose, and culture supernatants were harvested for insulin determination using enzyme-linked immunosorbent assay (ELISA). RESULTS The control group (no fibrin glue) and group 3 (with thrombin 50 U/mL and fibrinogen 10 mg/mL) had the highest insulin secretion in response to glucose stimulation. These were followed by groups 5 and 4 with 2.6 and 1.8 stimulation indexes, respectively. Group 2 (with thrombin 50 U/mL and fibrinogen 5 mg/mL) and group 6 (commercial kit with thrombin 250 U/mL and fibrinogen 75-115 mg/mL) had the lowest insulin response after glucose stimulation. CONCLUSION This study demonstrates that different fibrin glue formulations significantly impact pancreatic islets function. In the future, when using fibrin glue as a carrier for pancreatic islet transplantation, lower concentrations of fibrinogen and thrombin are recommended to obtain more viable and functional grafts.
Collapse
Affiliation(s)
- P Andrades
- Division of Transplant Immunology, Department of Surgery, University of Alabama in Birmingham, 1670 University Boulevard, Birmingham, AL 35294, USA.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Asiedu CK, Goodwin KJ, Balgansuren G, Jenkins SM, Le Bas-Bernardet S, Jargal U, Thomas JM, Neville DM. Retraction: Elevated T Regulatory Cells in Long-Term Stable Transplant Tolerance in Rhesus Macaques Induced by Anti-CD3 Immunot oxin and Deoxyspergualin. J Immunol 2006; 177:2023. [PMID: 16849517 DOI: 10.4049/jimmunol.177.3.2023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
21
|
Thomas J, Goodwin K, Rodriguez C, Balgansuren G, Asiedu C, Andrades P, Neville D. Il-10 and Tregs in Rhesus Macaques (Rm) with Resolute, Drug-Free, Pancreas Islet Allograft (Pitx) Tolerance for >6 Years. Clin Immunol 2006. [DOI: 10.1016/j.clim.2006.04.404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Asiedu CK, Goodwin KJ, Balgansuren G, Jenkins SM, Le Bas-Bernardet S, Jargal U, Neville DM, Thomas JM. Elevated T Regulatory Cells in Long-Term Stable Transplant Tolerance in Rhesus Macaques Induced by Anti-CD3 Immunotoxin and Deoxyspergualin. J Immunol 2005; 175:8060-8. [PMID: 16339543 DOI: 10.4049/jimmunol.175.12.8060] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Regulatory T cells (Tregs) are implicated in immune tolerance and are variably dependent on IL-10 for in vivo function. Brief peritransplant treatment of multiple nonhuman primates (NHP) with anti-CD3 immunotoxin and deoxyspergualin has induced stable (5-10 years) rejection-free tolerance to MHC-mismatched allografts, which associated with sustained elevations in serum IL-10. In this study, we demonstrate that resting and activated PBMC from long-term tolerant NHP recipients are biased to secrete high levels of IL-10, compared with normal NHP PBMC. Although IL-10-producing CD4+ Tregs (type 1 regulatory cells (TR1)/IL-10 Tregs) were undetectable (<0.5%) in normal rhesus monkeys, 7.5 +/- 1.7% of circulating CD4+ T cells of tolerant rhesus recipients expressed IL-10. In addition to this >15-fold increase in Tr1/IL-10 Tregs, the tolerant monkeys exhibited a nearly 3-fold increase in CD4+CD25+ Tregs, 8.1 +/- 3.0% of CD4 T cells vs 2.8 +/- 1.4% in normal cohorts (p < 0.02). The frequency of CD4+CD25+IL-10+ cells was elevated 5-fold in tolerant vs normal NHP (1.8 +/- 0.9% vs 0.4 +/- 0.2%). Rhesus CD4+CD25+ Tregs exhibited a memory phenotype, and expressed high levels of Foxp3 and CTLA-4 compared with CD4+CD25- T cells. Also, NHP CD4+CD25+ Tregs proliferated poorly after activation and suppressed proliferation of CD4+CD25- effector T cells, exhibiting regulatory properties similar to rodent and human CD4+CD25+ Tregs. Of note, depletion of CD4+CD25+ Tregs restored indirect pathway antidonor responses in tolerant NHP. Our study demonstrates an expanded presence of Treg populations in tolerant NHP recipients, suggesting that these adaptations may be involved in maintenance of stable tolerance.
Collapse
Affiliation(s)
- Clement K Asiedu
- Department of Surgery, Division of Transplant Immunology, University of Alabama, Birmingham, AL 35294
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Hagihara M, Hiraga S, Tsuchida F, Morita N, Kanai N, Balgansuren G, Munkhbat B, Masuko K, Yamamoto K, Kato S, Tsuji K. T-cell clonal change after allo-kidney transplantation in humans. Scand J Immunol 1998; 48:300-6. [PMID: 9743217 DOI: 10.1046/j.1365-3083.1998.00379.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Whether T cells circulating peripherally express changes at a clonal level after renal transplantation is uncertain. To clarify this issue, we analyzed T-cell clonality of peripheral blood lymphocytes (PBLs) in 12 renal transplant recipients by a novel polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) method that can discriminate T-cell clones with different T-cell receptor (TCR) Vbeta motifs. The PCR-SSCP study showed that after transplantation, only a few distinct T-cell clonotypes accumulated in the absence of clinical episodes, irrespective of the compatibility of HLA antigens. In contrast, various T-cell clones appeared in cases of acute rejection (AR) and infection. These subsided immediately after the AR was resolved; however, they remained long after the resolution of the infection. In a case of AR followed by an infectious episode, distinct T-cell clones appeared concomitantly with each episode. Several of them disappeared or remained thereafter. In one case, significant numbers of accumulating bands were observed by in-vitro stimulation by mixed lymphocyte reaction (MLR); several were identical to those found in vivo. However, some of those that did not appear in vitro were apparent in vivo. In conclusion, the appearance of T-cell clonotypes at a peripheral level indicates the existence of immunologically activated T-cell clones, which were significantly affected by immunosuppressive therapy. It was also determined that the T-cell immune system is much more complicated in vivo than in vitro.
Collapse
Affiliation(s)
- M Hagihara
- Department of Transplantation Immunology, Tokai University School of Medicine, Tokai University Hospital, Kanagawa, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|